LRG1及CA19-9在胰腺癌患者血清中的表达及临床意义  

Expressions of sera LRG1 and CA19-9 in patients with pancreatic cancer and clinical significance

作　　者：周思思[1] 马颖才[1] 赵相[1] 张臻英 Zhou Sisi;Ma Yingcai;Zhao Xiang;Zhang Zhenying(Department of Gastroenterology,Qinghai Provincial People's Hospital,Qinghai Xining 810007,China)

机构地区：[1]青海省人民医院消化内科,青海西宁810007

出　　处：《现代肿瘤医学》2020年第7期1149-1152,共4页Journal of Modern Oncology

基　　金：青海省卫计委指导性计划课题项目(编号:2017wjzdx-29)。

摘　　要：目的:研究富含亮氨酸的α-2糖蛋白1(leucine rich alpha-2 glycoprotein 1,LRG1)在胰腺癌患者血清中的表达,探讨联合检测LRG1、CA19-9对胰腺癌的诊断价值。方法:共纳入50例胰腺癌患者、30例慢性胰腺炎患者、50例健康志愿者;分别采用酶联免疫吸附法(enzyme linked immunosorbent assay,ELISA法)检测三组血清中LRG1和CA19-9水平,分析其与肿瘤临床分期的关系,比较单独检测LRG1和CA19-9与两者联合检测诊断胰腺癌的敏感性和特异性。结果:与慢性胰腺炎组及健康查体组相比,胰腺癌组血清中LRG1和CA19-9水平明显偏高(P<0.01),慢性胰腺炎组和正常对照组比较差异无统计学意义(P>0.05);胰腺癌临床分期与患者血清LRG1水平相关,Ⅲ、Ⅳ期恶性肿瘤患者血清LRG1水平明显高于I、Ⅱ期恶性肿瘤患者,差异有统计学意义(P<0.05);联合检测LRG1、CA19-9受试者工作特征曲线下面积大于单独检测CA19-9(P<0.05)。结论:LRG1可作为胰腺癌诊断潜在的生物标志物,联合检测血清LRG1及CA19-9水平可提高胰腺癌的早期诊断率。Objective:To study the expression of leucine-rich alpha-2 glycoprotein 1(LRG1) and CA19-9 in sera of patients with pancreatic cancer and to explore their clinical significance.Methods:A total of 50 patients with pancreatic cancer,30 patients with chronic pancreatitis(CP),and 50 healthy volunteers were enrolled in the study.Serum LRG1 levels were assayed by enzyme-linked immunosorbent assay(ELISA),and then the levels of LRG1 and CA19-9 in sera were compared in the three groups.The relationship between serum LRG1 and clinical stage was analyzed statistically.Results:Compared with those of chronic pancreatitis group and healthy examination group,the levels of LRG1 and CA19-9 in pancreatic cancer group were significantly higher(P<0.01),and there was no significant difference between chronic pancreatitis group and normal control group(P>0.05).The stage of pancreatic cancer was correlated with the level of serum LRG1.The level of serum LRG1 in patients with stage Ⅲ and Ⅳ malignant tumor was significantly higher than that in patients with stage I and Ⅱ malignant tumor,and the difference was statistically significant(P<0.05).The areas under the receiver operating characteristic(ROC) curve(AUC) for combine detection of sera LRG1 and CA19-9 was significantly improved by combined detection of serum LRG1 and CA19-9 than detection of them lonely(P<0.05).Conclusion:LRG1 can be used as a potential biomarker for the diagnosis of pancreatic cancer.The diagnostic sensitivity is significantly improved by combined detection of sera LRG1 and CA19-9 than detection of them lonely.

关 键 词：胰腺癌 富含亮氨酸α-2糖蛋白1 CA19-9抗原 

分 类 号：R735.9[医药卫生—肿瘤]